PURPOSE OF REVIEW: The purpose of this study is to review and discuss recently published (2013-2014) experimental and clinical studies of intraprostatic injection therapy as an alternative treatment of lower urinary tract symptoms (LUTS).
RECENT FINDINGS: Recent focus has been on intraprostatic injection of botulinum toxin both with regard to mechanism of action and efficacy. In contrast to the promising findings in several previous studies, a recent large, randomized, placebo-controlled trial found no differences between onabotulinumtoxin A treatment and placebo. There is little new information on the use of anhydrous ethanol and agents such as NX-1207 and PRX302, which previously have been reported to have promising effects.
SUMMARY: Intraprostatic injection of different agents as a minimally invasive surgical therapy for LUTS associated with benign prostatic hyperplasia seems attractive and may have a potential as a treatment alternative, but so far, available results are not convincing. Further studies on the mechanisms of action of novel agents, and controlled clinical trials documenting their efficacy and side-effects when injected into the prostate are needed before their place in the treatment of benign prostatic hyperplasia/LUTS can be properly assessed.
Written by:
Andersson KE. Are you the author?
Institute for Regenerative Medicine, Wake Forest University School of Medicine, Department of Urology, Wake Forest Baptist Medical Center, Winston Salem, North Carolina, USA; Aarhus Institute for Advanced Sciences, Aarhus University, Aarhus, Denmark.
Reference: Curr Opin Urol. 2014 Oct 18. Epub ahead of print.
doi: 10.1097/MOU.0000000000000122
PubMed Abstract
PMID: 25333915